Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Novartis Pharmaceuticals Corporation
Current Parent Company: Novartis
Penalty: $35,000,000
Year: 2016
Date: October 5, 2016
Offense Group: government-contracting-related offenses
Primary Offense: False Claims Act and related
Secondary Offense: qui tam whistleblower lawsuit
Mega-Scandal: Improper Drug Marketing
Violation Description: In a qui tam whistleblower case in which there was no government intervention, Novartis agreed to pay $35 million to settle allegations it violated the False Claims Act by marketing the eczema cream Elidel for use on infants, even though it was only approved for older patients.
Level of Government: federal
Action Type: private litigation
Court: Eastern District of Pennsylvania
Civil or Criminal Case: civil
Case ID: 2:06-cv-03213
Case Name: United States of America ex rel. Donald R. Galmines v. Novartis Pharmaceuticals Corporation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: Switzerland
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.